# Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

> **NCT02316340** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 42 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Hydroxychloroquine
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02316340
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-11
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-04-16
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316340, "Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02316340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*